The present invention relates to a method for making holes in a layer (1) of heat-fusible material. According to the invention a layer of absorbent material (2) is placed in contact with a layer (1) of heat-fusible material, following which the layer of heat-fusible material is heated locally so that holes are formed in the material.

The present invention discloses a method and a computer program for optimizing the implementation of a maintenance program for maintenance units. In the method of the invention, an estimated duration is determined for each maintenance module, a periodic working capacity is determined for each serviceman carrying out maintenance programs and location data is determined for each maintenance unit. Fu...

The net has net ropes (1, 2) e.g. steel wire ropes, that are connected with each other, where each rope is connected with the other rope which is to be crossed only in successive cross points (3, 4). The rope which is to be crossed is connected to joints by compression or by welding, where the net is connected to a horizontal supporting rope in an installation location of the net and has a specifi...

QUE COMPRENDE: a) SOMETER UN MATERIAL DE BASE, A TRATAMIENTO FISICO Y/O QUIMICO, TAL COMO APLICAR UNA CAPA DE OXIDO INORGANICO SEPARADO DE LA FASE DE VAPOR O APLICAR UN PEGAMENTO TAL COMO POLIURETANO O POLIESTER; b) APLICAR SOBRE EL MATERIAL BASE AL MENOS UNA CAPA DE 5 A 50 um DE ESPESOR DE MATERIAL PLASTICO RESISTENTE A LA INTEMPERIE, EN SOLUCION Y/O DISPERSION QUE CONTIENE COLORANTES, AJUSTANDO ...

DONDE DICHOS COMPONENTES SON SENALES LUMINOSAS, DESVIOS, CIRCUITOS DE VIAS FERREAS, PASOS A NIVEL Y SISTEMAS DE INFORMACION AL PASAJERO. LA ARQUITECTURA COMPRENDE UNA PLATAFORMA DE AUTOMATIZACION QUE INCLUYE VARIOS MODULOS COMO: a) UN CPU CON MEMORIAS DE PROGRAMA PARA APLICACIONES RELEVANTES PARA LA SEGURIDAD Y APLICACIONES NO RELEVANTES PARA LA SEGURIDAD; b) UNA FUENTE DE ALIMENTACION DE CORRIENT...

SE REFIERE A UN VECTOR O PLASMIDO QUE COMPRENDE: A) UNA SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA UNA MOLECULA TERAPEUTICA; B) UNA SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA UNA MOLECULA REGULADORA. DICHA MOLECULA TERAPEUTICA ES UNA PROTEINA RECOMBINANTE PREFERIBLEMENTE UN ANTICUERPO MONOCLONAL SELECCIONADO DE ALEMTUZUMAB, UN FACTOR ESTIMULADOR DE COLONIAS DE GRANULOCITOS MACROFAGOS (GMCSF), LEUKINA,...

Resolving 4,5-dimethoxy-1-aminomethyl-benzocyclob utane (IV) comprises reacting (IV) with an optically active diacid (II); filtering or centrifuging to recover the salt (VII) of (S)-(IV) and treating with base to give (VIII). - Resolving 4,5-dimethoxy-1-aminomethyl-benzocyc lobutane of formula (IV) comprises reacting (IV) with an optically active diacid (II); filtering or centrifuging to recover t...

Disclosed are thiazolobenzoheterocycles of the general formulaIncluding their isomers, racemates, enantioners and salts thereof, as well as processes for preparing these compounds and medicaments containing them. Also disclosed are novel intermediates for preparing the foregoing compounds, these intermediates having the formula

The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.

A method of selecting anti-aggregation molecules with chaperone-like activity that have characteristics including binding to a native target molecule epitope with a high binding constant and are non-inhibitory to the biological activity of the target molecule. The method molecules denaturating a target molecule in the presence of presumptative antiaggregation molecules to prevent the target molecu...

The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A. The present invention further relates...

A person's voice input is received (1) and analyzed (3). A comparison is made to a stored voice print (4). The result of the comparison indicates whether the person is an impostor (6) or is a valid holder of a portable device.

A process for the polymerization of one or more alpha-olefins having at least 3 carbon atoms, which comprises contacting the monomer or monomers in a polar or non-polar solvent under polymerization conditions with a homogeneous catalyst system including (a) a cationic form of a racemic mixture of a chiral octahedral transition metal complex or of a non chiral octahedral transition metal complex, c...

The invention relates to pharmaceutical formulations comprising growth hormone, an amino acid selected from the group of Asp, Ile, Val, Leu or His, or a derivative of histidine, or a peptide comprising at least one basic amino acid and at least one acidic amino acid, and a non-ionic detergent, e.g. polysorbate or poloxamer. The formulation is stabilized against deamidation and aggregation. The for...

The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4+ T cells as well as shift the ongoing activation state into a preferred differentiated population of...

The invention relates to a method for detecting antibodies from body fluids by means of an immune reaction with tissue transglutaminase (tTG), with tTG-containing compounds, the antigenic structures, immunoreactive sequences or analogues thereof. The method may be used in the diagnosis and therapy control of diseases associated with an immune reaction against tTG, tTG-containing compounds, the ant...

Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amounts of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. An...